{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:33:31Z","timestamp":1793363611438,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.eururo.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T02:44:21Z","timestamp":1667443461000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3553-5710","authenticated-orcid":false,"given":"Sigrid V.","family":"Carlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Gustav","family":"Pihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.10.006_b0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/tau.2017.12.25","article-title":"Prostate cancer screening\u2014when to start and how to screen?","volume":"7","author":"Kohestani","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0010","unstructured":"Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands; 2022. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"10.1016\/j.eururo.2022.10.006_b0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.urology.2015.12.054","article-title":"The Memorial Sloan Kettering Cancer Center recommendations for prostate cancer screening","volume":"91","author":"Vickers","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2022.10.006_b0020","unstructured":"Carroll PR, Parsons JK, Box G, Carlsson S, Catalona WJ, Dahl D. NCCN clinical practice guidelines in oncology (NCCN guidelines). Prostate cancer early detection. Version 1.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf."},{"key":"10.1016\/j.eururo.2022.10.006_b0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3322\/caac.21392","article-title":"Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"67","author":"Smith","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2022.10.006_b0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","article-title":"Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians","volume":"158","author":"Qaseem","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2022.10.006_b0035","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2022.10.006_b0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.10.006_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.07.067","article-title":"Baseline prostate-specific antigen testing at a young age","volume":"61","author":"Loeb","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0055","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2022.10.006_b0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2022.10.006_b0065","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.10.006_b0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of Follow up in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol."},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2022.10.006_b0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1465-5101.2003.04402.x","article-title":"Determining the cause of death in randomized screening trial(s) for prostate cancer","volume":"92","author":"De Koning","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.10.006_b0080","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1093\/aje\/kwab155","article-title":"Clarifying the trade-offs of risk-stratified screening for prostate cancer: a cost-effectiveness study","volume":"190","author":"Hendrix","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eururo.2022.10.006_b0085","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1002\/cam4.3395","article-title":"Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios","volume":"9","author":"Getaneh","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2022.10.006_b0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12894-015-0117-3","article-title":"Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia","volume":"15","author":"Dantanarayana","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2022.10.006_b0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0105","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.juro.2015.11.062","article-title":"The effect of start and stop age at screening on the risk of being diagnosed with prostate cancer","volume":"195","author":"Godtman","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0110","unstructured":"National Board of Health and Welfare. Causes of death Sweden 2021. https:\/\/sdb.socialstyrelsen.se\/if_dor\/val.aspx."},{"key":"10.1016\/j.eururo.2022.10.006_b0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","article-title":"Screening for prostate cancer starting at age 50\u201354 years. a population-based cohort study","volume":"71","author":"Carlsson","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1258\/jms.2012.012071","article-title":"Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality","volume":"19","author":"Zhu","year":"2012","journal-title":"J Med Screen"},{"key":"10.1016\/j.eururo.2022.10.006_b0125","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/ijc.25846","article-title":"Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden","volume":"129","author":"Jonsson","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2022.10.006_b0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.10.006_b0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.10.006_b0140","doi-asserted-by":"crossref","unstructured":"Stinesen Kollberg K, Holmberg E, Josefsson A, Hugosson J, Arnsrud Godtman R. Prostate-specific antigen and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial. J Urol. In press. https:\/\/doi.org\/10.1097\/JU.0000000000002835.","DOI":"10.1097\/JU.0000000000002835"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2022.11.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822027154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822027154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:11:36Z","timestamp":1708459896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822027154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0302283822027154"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.10.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742397010.793596601","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}